Details of the Drug

General Information of Drug (ID: DMNOKBV)

Drug Name
Phenytoin
Synonyms
Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 252.27
Topological Polar Surface Area (xlogp) 2.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5-3 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.37 mL/min/kg [5]
Elimination
The majority of phenytoin is excreted as inactive metabolites in the bile, only estimated 1-5% of phenytoin is eliminated unchanged in the urine [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 42 hours [6]
Metabolism
The drug is metabolized via the CYP2C9 and CYP2C19 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.81963 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [5]
Vd
The volume of distribution (Vd) of drug is 0.75 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.02 mg/mL [3]
Chemical Identifiers
Formula
C15H12N2O2
IUPAC Name
5,5-diphenylimidazolidine-2,4-dione
Canonical SMILES
C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
InChI
InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
InChIKey
CXOFVDLJLONNDW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1775
ChEBI ID
CHEBI:8107
CAS Number
57-41-0
DrugBank ID
DB00252
TTD ID
D0E4DW
VARIDT ID
DR00431
INTEDE ID
DR1282
ACDINA ID
D00529

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [15]
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [16]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [18]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [18]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [18]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Phenytoin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Diazepam DM08E9O Moderate Increased metabolism of Phenytoin caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [119]
Zonisamide DM0DTF7 Moderate Increased metabolism of Phenytoin caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [120]
Primidone DM0WX6I Moderate Increased metabolism of Phenytoin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [121]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Phenytoin caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [122]
Methsuximide DM6L5VO Moderate Increased metabolism of Phenytoin caused by Methsuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [123]
Valproate DMCFE9I Moderate Increased plasma concentration of Phenytoin and Valproate due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [124]
Ethosuximide DMDZ9LT Moderate Increased metabolism of Phenytoin caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [123]
Cenobamate DMGOVHA Major Increased metabolism of Phenytoin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Tiagabine DMKSQG0 Moderate Increased metabolism of Phenytoin caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [126]
Stiripentol DMMSDOY Major Increased metabolism of Phenytoin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [127]
Brivaracetam DMSEPK8 Moderate Increased metabolism of Phenytoin caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [128]
Clonazepam DMTO13J Moderate Increased metabolism of Phenytoin caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [119]
Lacosamide DMVM6QR Minor Increased metabolism of Phenytoin caused by Lacosamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [128]
Phenobarbital DMXZOCG Moderate Increased metabolism of Phenytoin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [121]
Carbamazepine DMZOLBI Moderate Increased metabolism of Phenytoin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [129]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Phenytoin caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [130]
⏷ Show the Full List of 16 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Phenytoin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Accelerated clearance of Phenytoin due to the transporter induction by Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [128]
Methylergonovine DMBEX4O Moderate Increased metabolism of Phenytoin caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [131]
Clindamycin DM15HL8 Moderate Increased metabolism of Phenytoin caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [132]
Sucralfate DMP9HBO Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Sucralfate. Acne vulgaris [ED80] [133]
Repaglinide DM5SXUV Moderate Increased metabolism of Phenytoin caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [134]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Thioguanine. Acute myeloid leukaemia [2A60] [135]
Ivosidenib DM8S6T7 Major Increased metabolism of Phenytoin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [136]
Midostaurin DMI6E0R Major Increased metabolism of Phenytoin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [137]
Gilteritinib DMWQ4MZ Major Accelerated clearance of Phenytoin due to the transporter induction by Gilteritinib. Acute myeloid leukaemia [2A60] [138]
Oliceridine DM6MDCF Major Increased metabolism of Phenytoin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [131]
Emapalumab DMZG5WL Moderate Altered metabolism of Phenytoin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [128]
Mitotane DMU1GX0 Minor Increased metabolism of Phenytoin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [139]
Donepezil DMIYG7Z Moderate Increased metabolism of Phenytoin caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [140]
Metronidazole DMTIVEN Moderate Decreased metabolism of Phenytoin caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [141]
Siltuximab DMGEATB Moderate Altered metabolism of Phenytoin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [128]
Ivabradine DM0L594 Major Increased metabolism of Phenytoin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [128]
Bepridil DM0RKS4 Major Increased metabolism of Phenytoin caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [142]
Dronedarone DMA8FS5 Moderate Increased metabolism of Phenytoin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [143]
Nifedipine DMSVOZT Major Increased metabolism of Phenytoin caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [142]
Bedaquiline DM3906J Major Increased metabolism of Phenytoin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [128]
Buspirone DMBS632 Major Increased metabolism of Phenytoin caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [144]
Clorazepate DMC3JST Moderate Increased metabolism of Phenytoin caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [145]
Alprazolam DMC7XDN Moderate Increased metabolism of Phenytoin caused by Alprazolam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [119]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Phenytoin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [121]
Halazepam DMPFWO6 Moderate Increased metabolism of Phenytoin caused by Halazepam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [119]
Chlordiazepoxide DMTN5XI Moderate Increased metabolism of Phenytoin caused by Chlordiazepoxide mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [119]
Clobazam - Lundbeck DMW1OQ0 Moderate Increased metabolism of Phenytoin caused by Clobazam - Lundbeck mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [119]
Oxazepam DMXNZM4 Moderate Increased metabolism of Phenytoin caused by Oxazepam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [119]
Voriconazole DMAOL2S Major Increased metabolism of Phenytoin caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [146]
Posaconazole DMUL5EW Moderate Increased metabolism of Phenytoin caused by Posaconazole mediated induction of UGT. Aspergillosis [1F20] [128]
Montelukast DMD157S Moderate Increased metabolism of Phenytoin caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [147]
Aminophylline DML2NIB Moderate Increased metabolism of Phenytoin caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [148]
Roflumilast DMPGHY8 Moderate Increased metabolism of Phenytoin caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [149]
Methylphenidate DM7SJD6 Minor Decreased metabolism of Phenytoin caused by Methylphenidate mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [150]
Desipramine DMT2FDC Moderate Decreased metabolism of Phenytoin caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [151]
Tindamax DM3OWT4 Moderate Decreased metabolism of Phenytoin caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [141]
Clarithromycin DM4M1SG Moderate Increased metabolism of Phenytoin caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [152]
Sulfamethoxazole DMB08GE Minor Increased plasma concentration of Phenytoin and Sulfamethoxazole due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [153]
Ceftriaxone DMCEW64 Minor Increased plasma concentration of Phenytoin and Ceftriaxone due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [153]
Troleandomycin DMUZNIG Moderate Increased metabolism of Phenytoin caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [152]
Telithromycin DMZ4P3A Major Increased metabolism of Phenytoin caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [128]
Retigabine DMGNYIH Moderate Increased metabolism of Phenytoin caused by Retigabine mediated induction of UGT. Behcet disease [4A62] [154]
Lamotrigine DM8SXYG Moderate Increased metabolism of Phenytoin caused by Lamotrigine mediated induction of UGT. Bipolar disorder [6A60] [155]
Cariprazine DMJYDVK Moderate Increased metabolism of Phenytoin caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [156]
Erdafitinib DMI782S Major Increased metabolism of Phenytoin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [157]
Pexidartinib DMS2J0Z Major Decreased metabolism of Phenytoin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [158]
Nitazoxanide DMOWLVG Moderate Increased plasma concentration of Phenytoin and Nitazoxanide due to competitive binding of plasma proteins. Bowel habit change [ME05] [159]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Phenytoin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [160]
Lapatinib DM3BH1Y Moderate Increased metabolism of Phenytoin caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [131]
HKI-272 DM6QOVN Major Increased metabolism of Phenytoin caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [131]
LY2835219 DM93VBZ Major Increased metabolism of Phenytoin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [161]
Exemestane DM9HPW3 Moderate Increased metabolism of Phenytoin caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [162]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Phenytoin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [163]
Tucatinib DMBESUA Major Increased metabolism of Phenytoin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [164]
Alpelisib DMEXMYK Major Increased metabolism of Phenytoin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [165]
Thiotepa DMIZKOP Moderate Increased metabolism of Phenytoin caused by Thiotepa mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [166]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Phenytoin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [163]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Phenytoin caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [167]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Phenytoin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [168]
Toremifene DMQYUWG Major Increased metabolism of Phenytoin caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [169]
Bosutinib DMTI8YE Major Increased metabolism of Phenytoin caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [170]
Estradiol DMUNTE3 Moderate Increased metabolism of Phenytoin caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [171]
Atorvastatin DMF28YC Moderate Increased metabolism of Phenytoin caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [172]
Macitentan DMP79A1 Major Increased metabolism of Phenytoin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [173]
Secobarbital DM14RF5 Moderate Increased metabolism of Phenytoin caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [121]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Phenytoin caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [174]
PF-04449913 DMSB068 Major Increased metabolism of Phenytoin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [175]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Phenytoin caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [176]
Anisindione DM2C48U Moderate Increased metabolism of Phenytoin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [177]
Regorafenib DMHSY1I Moderate Increased metabolism of Phenytoin caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [178]
Irinotecan DMP6SC2 Major Increased metabolism of Phenytoin caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [179]
Intedanib DMSTA36 Major Accelerated clearance of Phenytoin due to the transporter induction by Intedanib. Colorectal cancer [2B91] [180]
Drospirenone DM1A9W3 Major Increased metabolism of Phenytoin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [163]
Levonorgestrel DM1DP7T Major Increased metabolism of Phenytoin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [163]
Ulipristal DMBNI20 Moderate Increased metabolism of Phenytoin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [128]
Etonogestrel DMKA8J4 Major Increased metabolism of Phenytoin caused by Etonogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [163]
Norgestimate DMYP4XC Major Increased metabolism of Phenytoin caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [181]
Atracurium DM42HXN Moderate Increased metabolism of Phenytoin caused by Atracurium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [182]
Mivacurium DM473VD Moderate Increased metabolism of Phenytoin caused by Mivacurium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [182]
Bupivacaine DM4PRFC Minor Increased plasma concentration of Phenytoin and Bupivacaine due to competitive binding of plasma proteins. Corneal disease [9A76-9A78] [128]
Methohexital DM7YMIT Moderate Increased metabolism of Phenytoin caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [121]
Pancuronium DMB0VY8 Moderate Increased metabolism of Phenytoin caused by Pancuronium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [182]
Alfentanil DMVO0UB Moderate Increased metabolism of Phenytoin caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [183]
Nimodipine DMQ0RKZ Major Increased metabolism of Phenytoin caused by Nimodipine mediated induction of CYP450 enzyme. Coronary vasospastic disease [BA85] [184]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Phenytoin caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [148]
Methadone DMTW6IU Major Increased metabolism of Phenytoin caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [185]
Mycophenolic acid DMU65NK Minor Increased plasma concentration of Phenytoin and Mycophenolic acid due to competitive binding of plasma proteins. Crohn disease [DD70] [186]
Mifepristone DMGZQEF Moderate Increased metabolism of Phenytoin caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [187]
Osilodrostat DMIJC9X Major Increased metabolism of Phenytoin caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [128]
Ivacaftor DMZC1HS Major Increased metabolism of Phenytoin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [131]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Phenytoin and Ethanol. Cystitis [GC00] [131]
MK-8228 DMOB58Q Moderate Accelerated clearance of Phenytoin due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [131]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Phenytoin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [188]
Aprepitant DM053KT Moderate Increased metabolism of Phenytoin caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [189]
Sertraline DM0FB1J Moderate Decreased metabolism of Phenytoin caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [131]
Trimipramine DM1SC8M Moderate Decreased metabolism of Phenytoin caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Imipramine DM2NUH3 Moderate Decreased metabolism of Phenytoin caused by Imipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Phenytoin caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [190]
Vilazodone DM4LECQ Moderate Increased metabolism of Phenytoin caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [191]
Paroxetine DM5PVQE Moderate Antagonize the effect of Phenytoin when combined with Paroxetine. Depression [6A70-6A7Z] [192]
Vortioxetine DM6F1PU Moderate Increased metabolism of Phenytoin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [193]
OPC-34712 DMHG57U Moderate Increased metabolism of Phenytoin caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [194]
Clomipramine DMINRKW Moderate Decreased metabolism of Phenytoin caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Amitriptyline DMK7F9S Moderate Decreased metabolism of Phenytoin caused by Amitriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Amoxapine DMKITQE Moderate Decreased metabolism of Phenytoin caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Mirtazapine DML53ZJ Moderate Increased metabolism of Phenytoin caused by Mirtazapine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [195]
Protriptyline DMNHTZI Moderate Decreased metabolism of Phenytoin caused by Protriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Doxepin DMPI98T Moderate Decreased metabolism of Phenytoin caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [151]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Phenytoin and Esketamine. Depression [6A70-6A7Z] [131]
Empagliflozin DMRF9YK Moderate Increased metabolism of Phenytoin caused by Empagliflozin mediated induction of UGT. Diabetes mellitus [5A10] [131]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Phenytoin caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [131]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Phenytoin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [171]
PMID28870136-Compound-48 DMPIM9L Moderate Increased metabolism of Phenytoin caused by PMID28870136-Compound-48 mediated induction of CYP450 enzyme. Discovery agent [N.A.] [148]
Ospemifene DMC4GEI Moderate Increased metabolism of Phenytoin caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [196]
Ingrezza DMVPLNC Major Increased metabolism of Phenytoin caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [197]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Phenytoin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [181]
Cannabidiol DM0659E Moderate Increased metabolism of Phenytoin caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [128]
Nicardipine DMCDYW7 Major Increased metabolism of Phenytoin caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [142]
Praziquantel DMOU1PK Major Increased metabolism of Phenytoin caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [198]
Bay 80-6946 DMLOS5R Major Accelerated clearance of Phenytoin due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [199]
Tazemetostat DMWP1BH Major Increased metabolism of Phenytoin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [200]
Solifenacin DMG592Q Moderate Increased metabolism of Phenytoin caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [201]
Mirabegron DMS1GYT Minor Increased metabolism of Phenytoin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [202]
Darifenacin DMWXLYZ Moderate Increased metabolism of Phenytoin caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [203]
Itraconazole DMCR1MV Moderate Increased metabolism of Phenytoin caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [131]
Caspofungin DMGQIPT Major Increased metabolism of Phenytoin caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [204]
Miconazole DMPMYE8 Moderate Decreased metabolism of Phenytoin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [205]
Ketoconazole DMPZI3Q Moderate Increased metabolism of Phenytoin caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [131]
Omeprazole DM471KJ Moderate Decreased metabolism of Phenytoin caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [206]
Cimetidine DMH61ZB Major Decreased metabolism of Phenytoin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [207]
Ripretinib DM958QB Major Increased metabolism of Phenytoin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [208]
Sunitinib DMCBJSR Major Increased metabolism of Phenytoin caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [131]
Avapritinib DMK2GZX Major Increased metabolism of Phenytoin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [128]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Phenytoin and Brimonidine. Glaucoma [9C61] [209]
Sulfinpyrazone DMEV954 Moderate Increased plasma concentration of Phenytoin and Sulfinpyrazone due to competitive binding of plasma proteins. Gout [FA25] [128]
Ergotamine DMKR3C5 Moderate Increased metabolism of Phenytoin caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [131]
Eplerenone DMF0NQR Minor Increased metabolism of Phenytoin caused by Eplerenone mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [151]
Boceprevir DMBSHMF Major Increased metabolism of Phenytoin caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [210]
PSI-7977 DMLSUWZ Major Accelerated clearance of Phenytoin due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [128]
Simeprevir DMLUA9D Major Increased metabolism of Phenytoin caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [211]
Telaprevir DMMRV29 Major Increased metabolism of Phenytoin caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [212]
ABT-267 DMNQ869 Major Increased metabolism of Phenytoin caused by ABT-267 mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [128]
Daclatasvir DMSFK9V Major Increased metabolism of Phenytoin caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [128]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Phenytoin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [131]
Rifampin DMA8J1G Major Increased metabolism of Phenytoin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [213]
Rifapentine DMCHV4I Moderate Increased metabolism of Phenytoin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [214]
Pretomanid DMDYA31 Major Increased metabolism of Phenytoin caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [215]
MK-1439 DM215WE Major Increased metabolism of Phenytoin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [216]
Delavirdine DM3NF5G Major Increased metabolism of Phenytoin caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [217]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Phenytoin caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [218]
Cobicistat DM6L4H2 Major Increased metabolism of Phenytoin caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Phenytoin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [219]
Efavirenz DMC0GSJ Moderate Increased metabolism of Phenytoin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [220]
Dolutegravir DMCZGRE Major Increased metabolism of Phenytoin caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Saquinavir DMG814N Moderate Increased metabolism of Phenytoin caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [219]
Elvitegravir DMG9B1U Major Increased metabolism of Phenytoin caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Etravirine DMGV8QU Major Increased metabolism of Phenytoin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [221]
Lopinavir DMITQS0 Major Increased metabolism of Phenytoin caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [131]
Rilpivirine DMJ0QOW Major Increased metabolism of Phenytoin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [222]
Amprenavir DMLMXE0 Moderate Increased metabolism of Phenytoin caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [218]
Darunavir DMN3GCH Major Increased metabolism of Phenytoin caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [188]
Atazanavir DMSYRBX Moderate Increased metabolism of Phenytoin caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [219]
GSK1265744 DMT8J0I Major Increased metabolism of Phenytoin caused by GSK1265744 mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [223]
Ritonavir DMU764S Moderate Increased metabolism of Phenytoin caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [218]
Raltegravir DMYURI6 Minor Increased metabolism of Phenytoin caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [188]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Phenytoin caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [131]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Phenytoin and Mipomersen. Hyper-lipoproteinaemia [5C80] [224]
Clofibrate DMPC1J7 Minor Increased plasma concentration of Phenytoin and Clofibrate due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [225]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Phenytoin and BMS-201038. Hyper-lipoproteinaemia [5C80] [226]
Paricalcitol DMYBV3G Moderate Increased metabolism of Phenytoin caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [174]
Losartan DM72JXH Moderate Increased metabolism of Phenytoin caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [227]
Nisoldipine DM7ISKJ Major Increased metabolism of Phenytoin caused by Nisoldipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [142]
Levamlodipine DM92S6N Major Increased metabolism of Phenytoin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [142]
Isradipine DMA5XGH Major Increased metabolism of Phenytoin caused by Isradipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [142]
Diltiazem DMAI7ZV Moderate Increased metabolism of Phenytoin caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [228]
Amlodipine DMBDAZV Major Increased metabolism of Phenytoin caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [142]
Diazoxide DML1538 Moderate Increased metabolism of Phenytoin caused by Diazoxide mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [229]
Felodipine DMOSW35 Major Increased metabolism of Phenytoin caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [142]
Quinapril DMR8H31 Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [128]
Tolvaptan DMIWFRL Major Increased metabolism of Phenytoin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [128]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Phenytoin caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [230]
Liothyronine DM6IR3P Moderate Increased plasma concentration of Phenytoin and Liothyronine due to competitive binding of plasma proteins. Hypo-thyroidism [5A00] [128]
Levothyroxine DMHN027 Moderate Increased metabolism of Phenytoin caused by Levothyroxine mediated induction of CYP450 enzyme. Hypo-thyroidism [5A00] [128]
Pirfenidone DM6VZFQ Moderate Increased metabolism of Phenytoin caused by Pirfenidone mediated induction of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [128]
Febuxostat DMDEXQ0 Minor Increased metabolism of Phenytoin caused by Febuxostat mediated induction of UGT. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [128]
Lesinurad DMUR64T Moderate Increased metabolism of Phenytoin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [231]
TP-434 DM5A31S Major Increased metabolism of Phenytoin caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [232]
Suvorexant DM0E6S3 Major Increased metabolism of Phenytoin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [233]
Amobarbital DM0GQ8N Moderate Increased metabolism of Phenytoin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [121]
Ramelteon DM7IW9J Moderate Increased metabolism of Phenytoin caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [234]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Phenytoin caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [235]
Flurazepam DMAL4G0 Moderate Increased metabolism of Phenytoin caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [119]
Triazolam DMETYK5 Moderate Increased metabolism of Phenytoin caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [119]
Pentobarbital DMFNH7L Moderate Increased metabolism of Phenytoin caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [121]
Zaleplon DMGFWSM Moderate Increased metabolism of Phenytoin caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [236]
Tasimelteon DMLOQ1V Major Increased metabolism of Phenytoin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [237]
Zolpidem DMWOSKJ Moderate Increased metabolism of Phenytoin caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [128]
Quazepam DMY4D87 Moderate Increased metabolism of Phenytoin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [119]
Estazolam DMZGXUM Moderate Increased metabolism of Phenytoin caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [119]
Remimazolam DMLVSYX Moderate Increased metabolism of Phenytoin caused by Remimazolam mediated induction of CYP450 enzyme. Labour/delivery anaesthesia complication [JB0C] [119]
Naloxegol DML0B41 Major Increased metabolism of Phenytoin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [128]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Methotrexate. Leukaemia [2A60-2B33] [128]
Crizotinib DM4F29C Major Increased metabolism of Phenytoin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [131]
Brigatinib DM7W94S Major Increased metabolism of Phenytoin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [238]
Ceritinib DMB920Z Major Increased metabolism of Phenytoin caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [239]
Erlotinib DMCMBHA Moderate Increased metabolism of Phenytoin caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [240]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Phenytoin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [241]
PF-06463922 DMKM7EW Major Increased metabolism of Phenytoin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [242]
Osimertinib DMRJLAT Major Increased metabolism of Phenytoin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [131]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Phenytoin due to the transporter induction by BIBW 2992. Lung cancer [2C25] [243]
Pralsetinib DMWU0I2 Major Increased metabolism of Phenytoin caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [244]
Capmatinib DMYCXKL Major Increased metabolism of Phenytoin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [245]
Selpercatinib DMZR15V Major Increased metabolism of Phenytoin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [128]
Artemether DM48QOT Major Increased metabolism of Phenytoin caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [131]
Artesunate DMR27C8 Moderate Increased metabolism of Phenytoin caused by Artesunate mediated induction of UGT. Malaria [1F40-1F45] [246]
Chloroquine DMSI5CB Moderate Increased metabolism of Phenytoin caused by Chloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [131]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Phenytoin when combined with Hydroxychloroquine. Malaria [1F40-1F45] [131]
Quinine DMSWYF5 Moderate Increased metabolism of Phenytoin caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [247]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [248]
Idelalisib DM602WT Major Accelerated clearance of Phenytoin due to the transporter induction by Idelalisib. Mature B-cell leukaemia [2A82] [249]
GDC-0199 DMH0QKA Major Increased metabolism of Phenytoin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [250]
IPI-145 DMWA24P Major Increased metabolism of Phenytoin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [251]
Acalabrutinib DM7GCVW Major Increased metabolism of Phenytoin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [252]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Clofarabine. Mature B-cell lymphoma [2A85] [253]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Phenytoin caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [254]
Ibrutinib DMHZCPO Major Increased metabolism of Phenytoin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [128]
Vincristine DMINOX3 Moderate Accelerated clearance of Phenytoin due to the transporter induction by Vincristine. Mature B-cell lymphoma [2A85] [255]
Teniposide DMLW57T Moderate Increased metabolism of Phenytoin caused by Teniposide mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [256]
Ponatinib DMYGJQO Moderate Increased metabolism of Phenytoin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [131]
Arry-162 DM1P6FR Moderate Increased metabolism of Phenytoin caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [131]
Selumetinib DMC7W6R Major Increased metabolism of Phenytoin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [257]
LGX818 DMNQXV8 Major Increased metabolism of Phenytoin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [258]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Phenytoin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [131]
Estrone DM5T6US Moderate Increased metabolism of Phenytoin caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [163]
Conjugated estrogens DMLT0E1 Moderate Increased metabolism of Phenytoin caused by Conjugated estrogens mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [163]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Phenytoin caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [181]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Phenytoin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [259]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Phenytoin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [188]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Phenytoin caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [131]
Rimegepant DMHOAUG Major Increased metabolism of Phenytoin caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [260]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Phenytoin and Lasmiditan. Migraine [8A80] [261]
Exjade DMHPRWG Moderate Increased metabolism of Phenytoin caused by Exjade mediated induction of UGT. Mineral absorption/transport disorder [5C64] [131]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Phenytoin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [188]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Phenytoin caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [174]
Flibanserin DM70DTN Major Increased metabolism of Phenytoin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [262]
Midazolam DMXOELT Moderate Increased metabolism of Phenytoin caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [119]
Panobinostat DM58WKG Major Increased metabolism of Phenytoin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [263]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Phenytoin and Thalidomide. Multiple myeloma [2A83] [264]
Siponimod DM2R86O Major Increased metabolism of Phenytoin caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [131]
Deflazacort DMV0RNS Major Increased metabolism of Phenytoin caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [128]
Rifabutin DM1YBHK Moderate Increased metabolism of Phenytoin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [213]
Romidepsin DMT5GNL Moderate Increased metabolism of Phenytoin caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [265]
Fedratinib DM4ZBK6 Major Increased metabolism of Phenytoin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [128]
Nilotinib DM7HXWT Major Increased metabolism of Phenytoin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [266]
Imatinib DM7RJXL Major Decreased metabolism of Phenytoin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [267]
Vorapaxar DMA16BR Major Increased metabolism of Phenytoin caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [268]
Modafinil DMYILBE Moderate Increased metabolism of Phenytoin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [131]
Rolapitant DM8XP26 Major Increased metabolism of Phenytoin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [128]
Netupitant DMEKAYI Major Increased metabolism of Phenytoin caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [131]
Ondansetron DMOTQ1I Moderate Increased metabolism of Phenytoin caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [128]
E-2007 DMJDYNQ Moderate Increased metabolism of Phenytoin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [128]
Bupropion DM5PCS7 Moderate Increased metabolism of Phenytoin caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [131]
Entrectinib DMMPTLH Major Increased metabolism of Phenytoin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [269]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Phenytoin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [270]
S-297995 DM26IH8 Major Increased metabolism of Phenytoin caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [271]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Phenytoin and Apraclonidine. Optic nerve disorder [9C40] [209]
Valdecoxib DMAY7H4 Moderate Increased metabolism of Phenytoin caused by Valdecoxib mediated induction of CYP450 enzyme. Osteoarthritis [FA00-FA05] [272]
Olaparib DM8QB1D Major Increased metabolism of Phenytoin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [131]
Rucaparib DM9PVX8 Moderate Increased metabolism of Phenytoin caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [273]
MK-4827 DMLYGH4 Moderate Accelerated clearance of Phenytoin due to the transporter induction by MK-4827. Ovarian cancer [2C73] [274]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Phenytoin and Dextropropoxyphene. Pain [MG30-MG3Z] [275]
Butorphanol DM5KYPJ Major Increased metabolism of Phenytoin caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [131]
Aspirin DM672AH Minor Increased plasma concentration of Phenytoin and Aspirin due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [276]
Ibuprofen DM8VCBE Minor Increased plasma concentration of Phenytoin and Ibuprofen due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [277]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Phenytoin and Prilocaine. Pain [MG30-MG3Z] [151]
Codeine DMJX6ZG Moderate Increased metabolism of Phenytoin caused by Codeine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [176]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Phenytoin and Buprenorphine. Pain [MG30-MG3Z] [278]
Hydrocodone DMQ2JO5 Major Increased metabolism of Phenytoin caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [131]
Acetaminophen DMUIE76 Moderate Increased metabolism of Phenytoin caused by Acetaminophen mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [279]
Meperidine DMX4GND Moderate Increased metabolism of Phenytoin caused by Meperidine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [280]
Oxycodone DMXLKHV Major Increased metabolism of Phenytoin caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [131]
Istradefylline DM20VSK Major Increased metabolism of Phenytoin caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [281]
Pimavanserin DMR7IVC Moderate Increased metabolism of Phenytoin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [282]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Phenytoin caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [131]
Macimorelin DMQYJIR Moderate Increased metabolism of Phenytoin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [283]
Lefamulin DME6G97 Major Accelerated clearance of Phenytoin due to the transporter induction by Lefamulin. Pneumonia [CA40] [284]
Prednisone DM2HG4X Moderate Increased metabolism of Phenytoin caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [230]
Choline salicylate DM8P137 Minor Increased plasma concentration of Phenytoin and Choline salicylate due to competitive binding of plasma proteins. Postoperative inflammation [1A00-CA43] [276]
Betamethasone DMAHJEF Moderate Increased metabolism of Phenytoin caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [230]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Phenytoin caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [230]
Bromfenac DMKB79O Moderate Increased metabolism of Phenytoin caused by Bromfenac mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [285]
Ergonovine DM0VEC1 Moderate Increased metabolism of Phenytoin caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [131]
Lonafarnib DMGM2Z6 Major Increased metabolism of Phenytoin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [286]
Progesterone DMUY35B Moderate Increased metabolism of Phenytoin caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [163]
ABIRATERONE DM8V75C Major Increased metabolism of Phenytoin caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [287]
Enzalutamide DMGL19D Moderate Increased metabolism of Phenytoin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [288]
Relugolix DMK7IWL Major Increased metabolism of Phenytoin caused by Relugolix mediated induction of CYP450 enzyme. Prostate cancer [2C82] [289]
Darolutamide DMV7YFT Major Increased metabolism of Phenytoin caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [290]
Silodosin DMJSBT6 Moderate Accelerated clearance of Phenytoin due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [131]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Phenytoin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [128]
Apremilast DMTWS9E Major Increased metabolism of Phenytoin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [291]
Ixekizumab DMXW92T Moderate Altered metabolism of Phenytoin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [128]
Bosentan DMIOGBU Moderate Increased metabolism of Phenytoin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [131]
Treprostinil DMTIQF3 Moderate Increased metabolism of Phenytoin caused by Treprostinil mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [151]
Riociguat DMXBLMP Moderate Increased metabolism of Phenytoin caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [292]
Axitinib DMGVH6N Major Increased metabolism of Phenytoin caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [293]
Temsirolimus DMS104F Major Increased metabolism of Phenytoin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [131]
Sorafenib DMS8IFC Moderate Increased metabolism of Phenytoin caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [294]
Salsalate DM13P4C Minor Increased plasma concentration of Phenytoin and Salsalate due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [276]
Upadacitinib DM32B5U Major Increased metabolism of Phenytoin caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [295]
Tocilizumab DM7J6OR Moderate Altered metabolism of Phenytoin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [128]
Canakinumab DM8HLO5 Moderate Altered metabolism of Phenytoin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [128]
Tofacitinib DMBS370 Major Increased metabolism of Phenytoin caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [131]
Rilonacept DMGLUQS Moderate Altered metabolism of Phenytoin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [128]
Golimumab DMHZV7X Moderate Altered metabolism of Phenytoin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [128]
Dexamethasone DMMWZET Moderate Increased metabolism of Phenytoin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [230]
Nafcillin DMN9RPO Minor Increased plasma concentration of Phenytoin and Nafcillin due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [153]
Sarilumab DMOGNXY Moderate Altered metabolism of Phenytoin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [128]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Phenytoin and Leflunomide. Rheumatoid arthritis [FA20] [188]
Quetiapine DM1N62C Major Increased metabolism of Phenytoin caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [131]
Aripiprazole DM3NUMH Moderate Increased metabolism of Phenytoin caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [296]
Haloperidol DM96SE0 Major Increased metabolism of Phenytoin caused by Haloperidol mediated induction of CYP450 enzyme. Schizophrenia [6A20] [151]
Salicyclic acid DM2F8XZ Minor Increased plasma concentration of Phenytoin and Salicyclic acid due to competitive binding of plasma proteins. Seborrhoeic dermatitis [EA81] [276]
Fentanyl DM8WAHT Major Increased metabolism of Phenytoin caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [131]
Avanafil DM75CXN Moderate Increased metabolism of Phenytoin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [297]
Tadalafil DMJZHT1 Moderate Increased metabolism of Phenytoin caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [128]
Voxelotor DMCS6M5 Major Increased metabolism of Phenytoin caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [298]
LDE225 DMM9F25 Major Increased metabolism of Phenytoin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [299]
Gefitinib DM15F0X Moderate Increased metabolism of Phenytoin caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [240]
Larotrectinib DM26CQR Major Accelerated clearance of Phenytoin due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [131]
Methylprednisolone DM4BDON Moderate Increased metabolism of Phenytoin caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [230]
Cyclophosphamide DM4O2Z7 Moderate Increased metabolism of Phenytoin caused by Cyclophosphamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [166]
Vinblastine DM5TVS3 Moderate Increased metabolism of Phenytoin caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [255]
Docetaxel DMDI269 Moderate Increased metabolism of Phenytoin caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [300]
Trabectedin DMG3Y89 Major Increased metabolism of Phenytoin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [128]
LEE011 DMMX75K Major Increased metabolism of Phenytoin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [301]
Etoposide DMNH3PG Moderate Increased metabolism of Phenytoin caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [302]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [131]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Phenytoin caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [230]
Vandetanib DMRICNP Moderate Increased metabolism of Phenytoin caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [303]
Taxol DMUOT9V Moderate Increased metabolism of Phenytoin caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [304]
Vinorelbine DMVXFYE Moderate Accelerated clearance of Phenytoin due to the transporter induction by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [255]
Pitolisant DM8RFNJ Major Increased metabolism of Phenytoin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [128]
Disulfiram DMCL2OK Moderate Decreased metabolism of Phenytoin caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [305]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Phenytoin and Naltrexone. Substance abuse [6C40] [306]
Warfarin DMJYCVW Moderate Increased metabolism of Phenytoin caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [177]
Pomalidomide DMTGBAX Moderate Increased metabolism of Phenytoin caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [307]
Fostamatinib DM6AUHV Major Increased metabolism of Phenytoin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [308]
As-1670542 DMV05SW Major Increased metabolism of Phenytoin caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [309]
Apixaban DM89JLN Major Accelerated clearance of Phenytoin due to the transporter induction by Apixaban. Thrombosis [DB61-GB90] [128]
Brilinta DMBR01X Major Increased metabolism of Phenytoin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [310]
Dicumarol DMFQCB1 Moderate Increased metabolism of Phenytoin caused by Dicumarol mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [311]
Clopidogrel DMOL54H Minor Decreased metabolism of Phenytoin caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [312]
Cabozantinib DMIYDT4 Major Increased metabolism of Phenytoin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [313]
Pipecuronium DM5F84A Moderate Increased metabolism of Phenytoin caused by Pipecuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [182]
Doxacurium DMKE7L9 Moderate Increased metabolism of Phenytoin caused by Doxacurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [182]
Cisatracurium DMUZPJ5 Moderate Increased metabolism of Phenytoin caused by Cisatracurium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [182]
Rocuronium DMY9BMK Moderate Increased metabolism of Phenytoin caused by Rocuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [182]
Sirolimus DMGW1ID Major Increased metabolism of Phenytoin caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [131]
Mycophenolate mofetil DMPQAGE Minor Increased plasma concentration of Phenytoin and Mycophenolate mofetil due to competitive binding of plasma proteins. Transplant rejection [NE84] [186]
Tacrolimus DMZ7XNQ Major Increased metabolism of Phenytoin caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [131]
Canagliflozin DMFRM1I Moderate Increased metabolism of Phenytoin caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [131]
Linagliptin DMWFJTR Moderate Increased metabolism of Phenytoin caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [314]
Trimethoprim DMM7CHK Moderate Decreased metabolism of Phenytoin caused by Trimethoprim mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [315]
Elagolix DMB2C0E Moderate Increased metabolism of Phenytoin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [316]
Triamcinolone DM98IXF Moderate Increased metabolism of Phenytoin caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [230]
Betrixaban DM2C4RF Moderate Accelerated clearance of Phenytoin due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [317]
Disopyramide DM5SYZP Moderate Increased metabolism of Phenytoin caused by Disopyramide mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [318]
Mexiletine DMCTE9R Moderate Increased metabolism of Phenytoin caused by Mexiletine mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [319]
⏷ Show the Full List of 369 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Edetate calcium disodium E00487 6093170 Complexing agent
FD&C red no. 3 E00629 Not Available Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactitol monohydrate E00459 3067270 Diluent; Flavoring agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate E00445 2723816 Antimicrobial preservative
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Phenytoin 100 mg capsule 100 mg Extended Release Oral Capsule Oral
Phenytoin 200 mg capsule 200 mg Extended Release Oral Capsule Oral
Phenytoin 300 mg capsule 300 mg Extended Release Oral Capsule Oral
Phenytoin 100 mg capsule 100 mg Oral Capsule Oral
Phenytoin 30 mg capsule 30 mg Extended Release Oral Capsule Oral
Phenytoin 50 mg tablet 50 mg Chewable Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Gupta M, Tripp J: Phenytoin .
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Dilantin? FDA Label (injectable formulation)
7 Lachance S, Dhingra O, Bernstein J, Gagnon S, Savard C, Pelletier N, Boudreau N, Levesque A: Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials. Future Sci OA. 2015 Nov 1;1(4):FSO55. doi: 10.4155/fso.15.55. eCollection 2015 Nov.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Bergen DC: Pharmacokinetics of phenytoin: reminders and discoveries. Epilepsy Curr. 2009 Jul-Aug;9(4):102-4. doi: 10.1111/j.1535-7511.2009.01307.x.
10 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
11 Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
12 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
13 The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
14 Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
15 Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
16 Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
17 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
18 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
29 Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
30 Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
31 Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
32 In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
33 Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
34 Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
35 Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
36 Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
37 Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
38 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
39 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
40 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
41 Drug Interactions Flockhart Table
42 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
48 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
49 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
50 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
51 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
52 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
53 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
54 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
55 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
56 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
57 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
58 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
59 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
60 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
61 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
62 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
63 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
64 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
65 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
66 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
67 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
68 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
69 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
70 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
71 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
72 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
73 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
74 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
75 Drugs that may have potential CYP2B6 interactions.
76 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
77 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
78 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
79 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
80 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
81 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
82 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
83 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
84 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
85 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
86 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
87 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
88 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
89 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
90 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
91 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
92 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
93 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
94 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
95 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
96 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
97 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
98 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
99 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
100 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
101 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
102 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
103 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
104 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
105 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
106 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
107 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
108 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
109 Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
110 Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
111 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
112 Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
113 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
114 Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
115 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
116 In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
117 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
118 WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
119 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
120 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
121 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
122 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
123 Browne TR, Feldman RG, Buchanan RA, et al. "Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions." Neurology 33 (1983): 414-8. [PMID: 6403891]
124 Bourgeois BF "Pharmacologic interactions between valproate and other drugs." Am J Med 84 (1988): 29-33. [PMID: 3146222]
125 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
126 Product Information. Gabitril (tiagabine). Abbott Pharmaceutical, Abbott Park, IL.
127 Cazali N, Tran A, Treluyer JM, et al. "Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human." Br J Clin Pharmacol 56 (2003): 526-36. [PMID: 14651727]
128 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
129 Gratz ES, Theodore WH, Newmark ME, Kupferberg HJ, Porter RJ, Qu Z "Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures." Neurology 32 (1982): a223.
130 Bialer M, Soares-da-Silva P "Pharmacokinetics and drug interactions of eslicarbazepine acetate." Epilepsia 53 (2012): 935-46. [PMID: 22612290]
131 Cerner Multum, Inc. "Australian Product Information.".
132 Bernard A, Kermarrec G, Parize P, et.al "Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination." J Infect 71 (2015): 200-6. [PMID: 25936632]
133 McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624]
134 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
135 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
136 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
137 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
138 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
139 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
140 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
141 Blyden GT, Scavone JM, Greenblatt DJ "Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam." J Clin Pharmacol 28 (1988): 240-5. [PMID: 3360972]
142 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
143 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
144 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
145 Murphy A, Wilbur K "Phenytoin-diazepam interaction." Ann Pharmacother 37 (2003): 659-63. [PMID: 12708941]
146 Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage." Br J Clin Pharmacol 68 (2009): 462-3. [PMID: 19740405]
147 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
148 Crowley JJ, Cusack BJ, Jue SG, et al "Cigarette smoking and theophylline metabolism: effects of phenytoin." Clin Pharmacol Ther 42 (1987): 334-40. [PMID: 3621789]
149 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
150 Garrettson LK, Perel JM, Dayton PG "Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate." JAMA 207 (1969): 1053-6. [PMID: 5818377]
151 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
152 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
153 Dasgupta A, Dennen DA, Dean R, McLawhon RW "Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole." Clin Chem 37 (1991): 98-100. [PMID: 1988217]
154 Product Information. Potiga (ezogabine). GlaxoSmithKline, Research Triangle Park, NC.
155 American Epilepsy Society "FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory from the Ad Hoc ILAE/AES Task Force. [PMID: 33641454]
156 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
157 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
158 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
159 Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
160 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
161 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
162 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
163 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
164 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
165 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
166 de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S "Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin." Cancer Chemother Pharmacol 55 (2005): 507-10. [PMID: 15685452]
167 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
168 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
169 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
170 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
171 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
172 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
173 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
174 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
175 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
176 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
177 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
178 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
179 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
180 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
181 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
182 Liberman BA, Norman P, Hardy BG "Pancuronium-phenytoin interaction: a case of decreased duration of neuromuscular blockade." Int J Clin Pharmacol Ther Toxicol 26 (1988): 371-4. [PMID: 3220609]
183 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
184 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
185 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
186 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
187 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
188 Canadian Pharmacists Association.
189 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
190 Jalil P "Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports." J Neurol Neurosurg Psychiatry 55 (1992): 412-3. [PMID: 1602320]
191 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
192 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
193 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
194 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
195 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
196 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
197 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
198 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
199 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
200 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
201 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
202 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
203 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
204 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
205 Rolan PE, Somogyi AA, Drew MJ, et al "Phenytoin intoxication during treatment with parenteral miconazole." Br Med J (Clin Res Ed) 287 (1983): 1760. [PMID: 6416579]
206 Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
207 Algozzine GJ, Stewart RB, Springer PK "Decreased clearance of phenytoin with cimetidine." Ann Intern Med 95 (1981): 244-5. [PMID: 7258891]
208 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
209 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
210 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
211 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
212 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
213 Abajo FJ "Phenytoin interaction with rifampicin." Br Med J 297 (1988): 1048. [PMID: 3142625]
214 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
215 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
216 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
217 Product Information. Cerebyx (fosphenytoin). Parke-Davis, Morris Plains, NJ.
218 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
219 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
220 Anderson GD "Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs." Neurology 63(10 Suppl 4) (2004): S3-8. [PMID: 15557548]
221 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
222 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
223 Cerner Multum, Inc. "Canadian Product Information.".
224 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
225 Product Information. Atromid-S (clofibrate). Wyeth-Ayerst Laboratories, Philadelphia, PA.
226 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
227 Fischer TL, Pieper JA, Graff DW, et al. "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers." Clin Pharmacol Ther 72 (2002): 238-46. [PMID: 12235444]
228 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
229 Petro DJ, Vannucci RC, Kulin HE "Diazoxide-diphenylhydantoin interaction." J Pediatr 89 (1976): 331-2. [PMID: 940040]
230 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
231 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
232 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
233 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
234 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
235 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
236 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
237 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
238 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
239 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
240 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
241 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
242 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
243 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
244 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
245 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
246 Product Information. Artesunate (artesunate). Amivas, Frederick, MD.
247 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
248 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
249 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
250 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
251 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
252 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
253 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
254 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
255 Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
256 Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH "Increased teniposide clearance with concomitant anticonvulsant therapy." J Clin Oncol 10 (1992): 311-5. [PMID: 1732431]
257 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
258 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
259 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
260 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
261 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
262 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
263 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
264 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
265 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
266 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
267 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
268 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
269 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
270 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
271 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
272 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
273 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
274 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
275 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
276 Fraser DG, Ludden TM, Evens RP, Sutherland EW "Displacement of phenytoin from plasma binding sites by salicylate." Clin Pharmacol Ther 27 (1980): 165-9. [PMID: 7353334]
277 Bachmann KA, Schwartz JI, Forney RB Jr, et al "Inability of ibuprofen to alter single dose phenytoin disposition." Br J Clin Pharmacol 21 (1986): 165-9. [PMID: 3954932]
278 Center for Substance Abuse Treatment.?Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. [PMID: 22514846]
279 Bivins BA, Rapp RP, Griffen WO Jr, Blouin R, Bustrack J "Dopamine-phenytoin interaction. A cause of hypotension in the critically ill." Arch Surg 113 (1978): 245-9. [PMID: 637689]
280 Pond SM, Kretschzmar KM "Effect of phenytoin on meperidine clearance and normeperidine formation." Clin Pharmacol Ther 30 (1981): 680-6. [PMID: 7297025]
281 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
282 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
283 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
284 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
285 Gumbhirshah K, Cevallos WH, Decleene SA, Korthbradley JM "Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males." J Clin Pharmacol 37 (1997): 160-8. [PMID: 9055143]
286 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
287 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
288 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
289 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
290 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
291 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
292 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
293 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
294 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
295 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
296 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
297 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
298 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
299 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
300 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
301 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
302 Rodman JH, Murry DJ, Madden T, Santana VM "Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation." J Clin Oncol 12 (1994): 2390-7. [PMID: 7964955]
303 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
304 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
305 Brown CG, Kaminsky MJ, Feroli ER, Gurley HT "Delirium with phenytoin and disulfiram administration." Ann Emerg Med 12 (1983): 310-3. [PMID: 6625283]
306 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
307 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
308 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
309 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
310 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
311 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98. [PMID: 4397794]
312 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
313 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
314 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
315 Antoniou T, Gomes T, Mamdani MM, Juurlink DN "Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study." Br J Clin Pharmacol 71 (2011): 544-9. [PMID: 21395647]
316 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
317 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]
318 Aitio ML, Mansury L, Tala E, et al "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
319 Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN "Enhanced metabolism of mexiletine after phenytoin administration." Br J Clin Pharmacol 14 (1982): 219-23. [PMID: 7104173]